Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 5/2017

25.02.2017 | Original Article – Cancer Research

Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine

verfasst von: Yong-fang Ding, Zhen-hui Wu, Ying-jie Wei, Luan Shu, Yun-ru Peng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hepatocellular carcinoma (HCC) cases are closely associated with chronic inflammation and fibrosis which is known as hepatic inflammation-fibrosis-cancer (IFC) axis. The aim of this study is to elucidate the development characteristics of the rat HCC model based on IFC axis.

Methods

The diethylnitrosamine (DEN)-induced rat HCC, which presents a stepwise histopathological progression that is similar to human HCC, was used to analyze the features of the different stages (inflammation, fibrosis, cancer). Rats were injected DEN at a dose of 30 mg/kg body weight twice a week for 11 weeks and the animals were observed until week 20. Time series sera and organ samples from the DEN animal model were collected to evaluate the dynamic changes.

Results

It was found that serum biochemical indicators (AST, ALT, ALP, TP, T-BIL, IL-6, TNF-α) from DEN-treated group were higher than that from control group. Fibrosis-related index in serum and live tissue were increased, respectively, from week 4 after DEN treatment. The expression of TGF-β1 and α-SMA in DEN-treated group was higher than that in control group. JAK2/STAT3 signaling was significantly up-regulated in DEN-treated group compared to that in control group. The histological examination confirmed that the hepatocarcinogenesis model was successfully established, and 100% of the animals in the DEN-exposed group developed liver tumors at 20 weeks. According to the pathological changes, the model characterized resulted in three stages: the inflammation stage (week 2–6), the fibrosis stage (week 8–12), and the HCC stage (week 14–20).

Conclusions

The results suggested that the HCC development was associated with IFC axis. The serial progression of hepatocarcinogenesis was according to the sequence of hepatic inflammation, fibrosis and then hepatic tumor.
Literatur
Zurück zum Zitat Borbath I, Stärkel P (2011) Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. Acta Gastroenterol Belg 74:34–44PubMed Borbath I, Stärkel P (2011) Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. Acta Gastroenterol Belg 74:34–44PubMed
Zurück zum Zitat Calès P, Boursier J, Chaigneau J et al (2010) Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 30:1346–1354CrossRefPubMed Calès P, Boursier J, Chaigneau J et al (2010) Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 30:1346–1354CrossRefPubMed
Zurück zum Zitat Costentin CE, Roudot-Thraval F, Zafrani ES et al (2011) Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 54:1123–1129CrossRefPubMed Costentin CE, Roudot-Thraval F, Zafrani ES et al (2011) Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 54:1123–1129CrossRefPubMed
Zurück zum Zitat Cubero FJ (2016) Shutting off inflammation: a novel switch on hepatic stellate cells. Hepatology 63:1086–1089CrossRefPubMed Cubero FJ (2016) Shutting off inflammation: a novel switch on hepatic stellate cells. Hepatology 63:1086–1089CrossRefPubMed
Zurück zum Zitat Di Virgilio F (2014) Purinergic receptors in cancer and inflammation: from Rudolph Virchow to Geoff Burnstock. Purinergic signallling, vol 10. Springer, Netherlands, pp 657–658 Di Virgilio F (2014) Purinergic receptors in cancer and inflammation: from Rudolph Virchow to Geoff Burnstock. Purinergic signallling, vol 10. Springer, Netherlands, pp 657–658
Zurück zum Zitat Ding Y, Peng Y, Li J et al (2013) Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF-beta/Smad signalling. J Pharm Pharmacol 65:1373–1381CrossRefPubMed Ding Y, Peng Y, Li J et al (2013) Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF-beta/Smad signalling. J Pharm Pharmacol 65:1373–1381CrossRefPubMed
Zurück zum Zitat Elsharkawy AM, Mann DA (2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590–597.CrossRefPubMed Elsharkawy AM, Mann DA (2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590–597.CrossRefPubMed
Zurück zum Zitat Farazi PA, Depinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMed Farazi PA, Depinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMed
Zurück zum Zitat Hernandez–Gea V, Toffanin S, Friedman SL et al (2013) Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144:512–527CrossRef Hernandez–Gea V, Toffanin S, Friedman SL et al (2013) Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144:512–527CrossRef
Zurück zum Zitat Kishida N, Matsuda S, Itano O (2016) Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. BMC Gastroenterol 16:61. doi:10.1186/s12876-016-0477-5 CrossRefPubMedPubMedCentral Kishida N, Matsuda S, Itano O (2016) Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. BMC Gastroenterol 16:61. doi:10.​1186/​s12876-016-0477-5 CrossRefPubMedPubMedCentral
Zurück zum Zitat Knodell RG, Ishak KG, Black WC et al (1981) Forumlation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435CrossRefPubMed Knodell RG, Ishak KG, Black WC et al (1981) Forumlation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435CrossRefPubMed
Zurück zum Zitat Li J, Sun Z, Zhang J et al (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260:799–807CrossRefPubMed Li J, Sun Z, Zhang J et al (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260:799–807CrossRefPubMed
Zurück zum Zitat Ma W, Sze KM, Chan LK et al (2016) RhoE/ROCK regulates chemoresistance through NF-ΚB/IL-6/STAT3 signaling in hepatocellular carcinoma. Oncotarget 27:41445–41459. doi:10.18632/oncotarget.9441 Ma W, Sze KM, Chan LK et al (2016) RhoE/ROCK regulates chemoresistance through NF-ΚB/IL-6/STAT3 signaling in hepatocellular carcinoma. Oncotarget 27:41445–41459. doi:10.​18632/​oncotarget.​9441
Zurück zum Zitat Peng Y, Ding Y (2015) Pharmacokinetics and tissue distribution study of caudatin in normal and diethylnitrosamine-induced hepatocellular carcinoma model rats. Molecules 20:4225–4237CrossRefPubMed Peng Y, Ding Y (2015) Pharmacokinetics and tissue distribution study of caudatin in normal and diethylnitrosamine-induced hepatocellular carcinoma model rats. Molecules 20:4225–4237CrossRefPubMed
Zurück zum Zitat Santos NP, Colaco A, da Costa R M G (2014) N-diethylnitrosamine mouse hepatotoxicity: time-related effects on histology and oxidative stress. Exp Toxicol Pathol 66:429–436CrossRef Santos NP, Colaco A, da Costa R M G (2014) N-diethylnitrosamine mouse hepatotoxicity: time-related effects on histology and oxidative stress. Exp Toxicol Pathol 66:429–436CrossRef
Zurück zum Zitat Tachi Y, Hirai T, Miyata A et al (2015) Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 45:238–246. doi:10.1111/hepr.12331 CrossRefPubMed Tachi Y, Hirai T, Miyata A et al (2015) Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 45:238–246. doi:10.​1111/​hepr.​12331 CrossRefPubMed
Zurück zum Zitat Tyler PD, Mcdevitt JL, Sheu AY et al (2013) Seven-tesla magnetic resonance imaging accurately quantifies intratumoral uptake of therapeutic nanoparticles in the McA rat model of hepatocellular carcinoma: preclinical study in a rodent model. Investig Radiol 49:87–92CrossRef Tyler PD, Mcdevitt JL, Sheu AY et al (2013) Seven-tesla magnetic resonance imaging accurately quantifies intratumoral uptake of therapeutic nanoparticles in the McA rat model of hepatocellular carcinoma: preclinical study in a rodent model. Investig Radiol 49:87–92CrossRef
Zurück zum Zitat Uehara T, Pogribny I P, Rusyn I (2014) The DEN and CCl4-induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. Curr Protoc Pharmacol 66:14.30.1–14.30.10 Uehara T, Pogribny I P, Rusyn I (2014) The DEN and CCl4-induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. Curr Protoc Pharmacol 66:14.30.1–14.30.10
Zurück zum Zitat Wong WS, Janssen H L A (2015) Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 63:722–732CrossRefPubMed Wong WS, Janssen H L A (2015) Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 63:722–732CrossRefPubMed
Zurück zum Zitat Zhao H, Guo Y, Han R et al (2015) A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 31:31927–31943. doi:10.18632/oncotarget.5578 Zhao H, Guo Y, Han R et al (2015) A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 31:31927–31943. doi:10.​18632/​oncotarget.​5578
Metadaten
Titel
Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine
verfasst von
Yong-fang Ding
Zhen-hui Wu
Ying-jie Wei
Luan Shu
Yun-ru Peng
Publikationsdatum
25.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2364-z

Weitere Artikel der Ausgabe 5/2017

Journal of Cancer Research and Clinical Oncology 5/2017 Zur Ausgabe

Original Article – Clinical Oncology

The effectiveness of radiotherapy for leukemia cutis

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.